NIFTY 50

CLSA recommends 'sell' rating for Biocon

Updated : April 12, 2021 05:16:08 IST

The brokerage firm believes there won’t be any upside even in the case of a bull market and the share gains may disappoint
CLSA adds that the rising competitive intensity in the US and EU, weak cash flow and gradual market share gains from biologics launches keeps the risk of earning downgrades high
CLSA recommends 'sell' rating for Biocon
Published : April 12, 2021 05:16 PM IST

You May Also Like

Live TV

recommended for you